Literature DB >> 3054014

Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes.

Y Sawamura1, H Abe, T Aida, M Hosokawa, H Kobayashi.   

Abstract

The present investigation was conducted in order to examine the feasibility of isolating and growing glioma-infiltrating lymphocytes in vitro as possible effector cells for use in new adoptive immunotherapy. Eight surgical specimens obtained from patients with malignant astrocytomas were treated by enzyme dispersion; the cells were separated on a density gradient and grown in the presence of human recombinant interleukin-2. The cultured lymphocytes were tested for cell-surface markers by using monoclonal antibodies in a flow cytometric analysis. In all cases the glioma-derived lymphocytes were grown in culture for several weeks with substantial increases in cell numbers (at least 5 X 10(8) cells). The mature T cell population (CD3, 89%) was found to have an increased proportion of the cytotoxic/suppressor phenotype CD8 (55%) as compared to peripheral blood lymphocytes (PBL's). Eighty-six percent of the cultivated lymphocytes expressed HLA-DR. The IL-2 receptor was predominantly expressed on the helper subset (CD4-positive). Otherwise, anti-CD16, which specifically reacts with natural killer (NK) cells, did not stain significantly more of the cultured gliomaderived lymphocytes compared with lymphocyte-activated PBL's. These results corroborate the observations made with conventional immunohistochemical examination. It has been demonstrated that T lymphocytes isolated from human cancers are enriched for specific reactivity to their autochthonous tumor cells. These experiments support the possible use of glioma-infiltrating lymphocytes as a new treatment for patients with malignant glioma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3054014     DOI: 10.3171/jns.1988.69.5.0745

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.

Authors:  M G Kaplitt; J G Tjuvajev; D A Leib; J Berk; K D Pettigrew; J B Posner; D W Pfaff; S D Rabkin; R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Cell adhesion molecules acting between C6 glioma and endothelial cells.

Authors:  M Tamaki; M Aoyagi; I Morita; K Hirakawa; S Murota
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 7.  Recent developments on immunotherapy for brain cancer.

Authors:  Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

8.  Immune genes are associated with human glioblastoma pathology and patient survival.

Authors:  Elodie Vauléon; Avril Tony; Abderrahmane Hamlat; Amandine Etcheverry; Dan Cristian Chiforeanu; Philippe Menei; Jean Mosser; Véronique Quillien; Marc Aubry
Journal:  BMC Med Genomics       Date:  2012-09-14       Impact factor: 3.063

9.  Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system.

Authors:  H Kishima; K Shimizu; Y Miyao; E Mabuchi; K Tamura; M Tamura; M Sasaki; T Hakakawa
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

Review 10.  Immunological Evasion in Glioblastoma.

Authors:  Roxana Magaña-Maldonado; Elda Georgina Chávez-Cortez; Nora Karen Olascoaga-Arellano; Mariana López-Mejía; Fernando Manuel Maldonado-Leal; Julio Sotelo; Benjamín Pineda
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.